Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Kendi

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Cancer Treatment Reviews|May 4, 2024
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are goingMiguel Muniz, Charles L Loprinzi, Jacob J Orme, et al.
CA: a Cancer Journal for Clinicians|April 29, 2024
Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumorsAman Chauhan, Kelley Chan, Thorvardur R Halfdanarson, et al.
The Lancet. Oncology|June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trialKarim Fizazi, Ken Herrmann, Bernd J Krause, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Cancer Treatment Reviews|May 4, 2024
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are goingMiguel Muniz, Charles L Loprinzi, Jacob J Orme, et al.
CA: a Cancer Journal for Clinicians|April 29, 2024
Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumorsAman Chauhan, Kelley Chan, Thorvardur R Halfdanarson, et al.
The Lancet. Oncology|June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trialKarim Fizazi, Ken Herrmann, Bernd J Krause, et al.
Pageof 3